| Key roles of adjuvants in modern vaccines SG Reed, MT Orr, CB Fox Nature medicine 19 (12), 1597-1608, 2013 | 1518 | 2013 |
| Use of defined TLR ligands as adjuvants within human vaccines MS Duthie, HP Windish, CB Fox, SG Reed Immunological reviews 239 (1), 178-196, 2011 | 525 | 2011 |
| Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant RN Coler, S Bertholet, M Moutaftsi, JA Guderian, HP Windish, SL Baldwin, ... PloS one 6 (1), e16333, 2011 | 415 | 2011 |
| Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want H HogenEsch, DT O’Hagan, CB Fox npj Vaccines 3 (1), 51, 2018 | 371 | 2018 |
| Squalene emulsions for parenteral vaccine and drug delivery CB Fox Molecules 14 (9), 3286-3312, 2009 | 277 | 2009 |
| Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens NPH Knudsen, A Olsen, C Buonsanti, F Follmann, Y Zhang, RN Coler, ... Scientific reports 6 (1), 19570, 2016 | 261 | 2016 |
| Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses KO Saunders, E Lee, R Parks, DR Martinez, D Li, H Chen, RJ Edwards, ... Nature 594 (7864), 553-559, 2021 | 254 | 2021 |
| New generation adjuvants–from empiricism to rational design DT O’Hagan, CB Fox Vaccine 33, B14-B20, 2015 | 188 | 2015 |
| An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants CB Fox, J Haensler Expert review of vaccines 12 (7), 747-758, 2013 | 160 | 2013 |
| Detecting phase transitions in phosphatidylcholine vesicles by Raman microscopy and self-modeling curve resolution CB Fox, RH Uibel, JM Harris The Journal of Physical Chemistry B 111 (39), 11428-11436, 2007 | 153 | 2007 |
| A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika JH Erasmus, AP Khandhar, J Guderian, B Granger, J Archer, M Archer, ... Molecular Therapy 26 (10), 2507-2522, 2018 | 152 | 2018 |
| Working together: interactions between vaccine antigens and adjuvants CB Fox, RM Kramer, L Barnes V, QM Dowling, TS Vedvick Therapeutic advances in vaccines 1 (1), 7-20, 2013 | 128 | 2013 |
| 3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope–specific plasma cells and humoral immunity in nonhuman primates SP Kasturi, MAU Rasheed, C Havenar-Daughton, M Pham, T Legere, ... Science immunology 5 (48), eabb1025, 2020 | 127 | 2020 |
| Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations RC Anderson, CB Fox, TS Dutill, N Shaverdian, TL Evers, GR Poshusta, ... Colloids and Surfaces B: Biointerfaces 75 (1), 123-132, 2010 | 124 | 2010 |
| Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis MT Orr, CB Fox, SL Baldwin, SJ Sivananthan, E Lucas, S Lin, T Phan, ... Journal of Controlled Release 172 (1), 190-200, 2013 | 115 | 2013 |
| Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions CB Fox, RC Anderson, TS Dutill, Y Goto, SG Reed, TS Vedvick Colloids and Surfaces B: Biointerfaces 65 (1), 98-105, 2008 | 101 | 2008 |
| A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7 CB Fox, SJ Sivananthan, MS Duthie, J Vergara, JA Guderian, E Moon, ... Journal of nanobiotechnology 12, 1-9, 2014 | 97 | 2014 |
| Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide SM Alam, B Aussedat, Y Vohra, RR Meyerhoff, EM Cale, WE Walkowicz, ... Science translational medicine 9 (381), eaai7521, 2017 | 96 | 2017 |
| Adjuvants for Leishmania vaccines: from models to clinical application VS Raman, MS Duthie, CB Fox, G Matlashewski, SG Reed Frontiers in immunology 3, 144, 2012 | 96 | 2012 |
| SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung NK Routhu, N Cheedarla, VS Bollimpelli, S Gangadhara, VV Edara, L Lai, ... Nature communications 12 (1), 3587, 2021 | 95 | 2021 |
Joel M. HarrisProfessor of Chemistry, University of UtahEmail verificata su chem.utah.edu